Nicolas Girard, MD, PhD, discusses the final overall survival results from the MARIPOSA trial of amivantamab plus lazertinib in EGFR-mutant advanced non–small cell lung cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback